Bleeding and thrombosis associated with ventricular assist device therapy

Palak Shah, Udaya S. Tantry, Kevin P. Bliden, Paul A. Gurbel

Research output: Contribution to journalArticlepeer-review

Abstract

Over the past decade, continuous-flow rotary pumps have dramatically improved survival for patients with advanced systolic heart failure. Bleeding and thrombosis, however, continue to be the Achilles heel of left ventricular assist device (LVAD) therapy. There is a dynamic and complex interaction between the patient and pump. The net effect of a variety of hematologic derangements, such as hemolysis, high-molecular-weight von Willebrand degradation, platelet activation and diminished pulsatility, is poorly understood. A combination of these factors mediates the common adverse events of gastrointestinal bleeding, device thrombosis and stroke. In this review we incorporate information from translational investigations in LVAD patients to understand how continuous-flow pumps activate the coagulation system and platelets predisposing to thrombosis, while, in parallel, degrade high-molecular-weight von Willebrand factor and trigger abnormal angiogenesis predisposing to bleeding. Finally, we propose novel strategies to develop a personalized approach to anti-thrombotic monitoring and titration of anti-coagulants to minimize the bleeding and thrombotic event rates of future LVAD recipients.

Original languageEnglish (US)
Pages (from-to)1164-1173
Number of pages10
JournalJournal of Heart and Lung Transplantation
Volume36
Issue number11
DOIs
StatePublished - Nov 2017

Keywords

  • anti-thrombotic therapy
  • gastrointestinal bleeding
  • hemolysis
  • left ventricular assisted device
  • thrombosis

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Fingerprint Dive into the research topics of 'Bleeding and thrombosis associated with ventricular assist device therapy'. Together they form a unique fingerprint.

Cite this